Pfizer Q1: Headwinds And Tailwinds From COVID-19

The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.

SC2004_Pfizer_286009616_1200.jpg
Pfizer's biopharmaceutical revenues held up in the first quarter • Source: Shutterstock

More from Earnings

More from Business